Commercially available, uncoated elastomeric closures were examined in regard to a potential contribution of extracted compounds from the rubber stoppers to protein aggregation under worst-case conditions. All rubber stoppers were confirmed to comply with Ph. Eur. quality requirements. Extraction with 2-propanol under refluxconditions for 3 h led to closure-specific extraction profiles of the tested samples. One type of rubber stopper exhibited a considerably greater number and higher content of extractables. Four extracted compounds were identified as trialkyl benzene-1, 2, 4-tricarboxylates (trivial name: trimellitates), a substance class which is increasingly established as an alternative to phthalates. A highly concentrated aqueous solution of total extractables from this rubber stopper facilitated the formation of soluble and non-soluble high-molecular aggregates when incubated with model biopharmaceuticals (recombinant human immunoglobulin G (IgG) and recombinant erythropoietin (EPO)) under stress conditions (IgG: 60-64°C for 130 min, EPO: 55°C for 8 days). Furthermore, it was shown that the surfactant concentration (polysorbate 20, 0.1 m/v% vs. 1.0 m/v%) decisively influenced the formation of high-molecular aggregates. In case of EPO, the 10 fold increased concentration of surfactant was sufficient to prevent the aggregate formation completely.
Introduction
In recent years the development and thereby the number of marketing authorizations for biopharmaceuticals increased rapidly. Currently, more than 400 recombinant biopharmaceuticals (peptides and proteins) were already approved worldwide by May 2015. At the same time around 1300 additional recombinant biopharmaceuticals were counted as very promising candidates, of which around 80% already had entered the stage of pre-clinical studies respectively clinical trials [1] . Because of their size and structural properties protein molecules tend to aggregate, which involves a loss of biological activity and pharmacological efficacy [2] combined with an increased risk of causing undesirable immunogenic reactions [3] . This was shown for recombinant human growth hormone (hGh) [4] , Willebrandt factor VIII [5] and interferon beta [6] .
For enhancing their chemical and physical stabilization, biopharmaceutical formulations usually contain various excipients like buffer salts, antioxidants, chelating agents, and surfactants. Common surfactants in marketed biopharmaceuticals are polysorbate 20 and 80 (PS 20 and 80), which are used in a concentration range of 0.001-0.1% [7] . The choice of surfactant and the optimum concentration depend on e.g. formulation ingredients, protein concentration and the type of container [7] .
Biopharmaceuticals are mainly offered as liquid or lyophilized formulations in glass containers that are closed with elastomeric closures. Synthetic rubber closures are the first choice because of their higher purity and the remarkable material properties, particularly their elasticity. This elasticity leads to a tighter contact with the glass container and thus ensures integrity and sterility of the parental product. Furthermore, rubber has a sufficient resealing capability that allows repeated piercing by a needle [8] . Elasticity of the material is obtained by "vulcanization", a complex chemical procedure at high temperatures and pressure in the presence of various reagents like curing agents, activators, and accelerators. This vulcanization process leads to the desired cross-linked structure of the rubber. Further additives like plasticizers, fillers, antioxidants, and pigments are needed to achieve additional necessary material properties. These additives do not have any covalent binding to the polymer chains and subsequently may leach from the rubber stopper material into the medicinal product during its shelf life. Leaching should be minimized as leachables from the container closure system can negatively affect the medicinal product's safety, stability, and efficacy.
Extraction studies are the first step for evaluating potential leachables from a container closure component. Samples of the component are exposed to appropriate solvents at extreme conditions in order to maximize the extraction of all compounds capable to migrate. Ding et al. propose various solvents for the examination of the extractables from the elastomeric parts of single-use systems for biomanufacturing applications [9] . Since leachables are largely a subset of the extractables, obtaining the complete extraction profile enables an early evaluation of potential leachables and their risk assessment [10] .
Earlier work underlined the impact of the formulation on the potential leaching behaviour from rubber closures [11] . Especially the group of non-ionic polysorbates are suspected to force leaching out of the primary packaging due to their ability for changing the extraction behaviour of the aqueous drug formulation [11] . Accordingly, the compatibility of each parenteral drug product and its selected primary packaging system is verified within the marketing authorization procedure by conducting leachables studies at recommended storage temperature according to the current EMA [12] and FDA [13] [14] [15] guidelines.
Ph. Eur. 3.2.9 [16] and USP 〈3 8 1〉 [17] describe quality requirements for elastomeric closures intended to be used as a component of the container closure system for parenteral products. The chemical, biological (only USP) and functional tests requested are aimed to confirm the desired quality of elastomeric closures. The chemical quality parameters are studied with an aqueous test solution prepared by boiling a specific number of stoppers in water. This test solution is subsequently used to determine physicochemical parameters, as e.g. "Acidity/Alkalinity" or "Reducing Substances", and to perform tests on "Ammonium" and "Extractable Zinc". No other solvents with different polarities are requested by the pharmacopoeia although recently published recommendations underline the need of different extraction solvents for obtaining a complete summary of extractables and potential leachables from drug product packaging components [18] .
Interactions between container closure materials and biopharmaceuticals are of particular importance due to their potential impact on inducing protein aggregation: Silicone oil, a commonly used lubricant for glass vials and rubber stoppers, was discussed in the context of protein aggregation [19] as well as particles derived from equipment surfaces [7] . Also, soluble tungsten species, which originated from pins used for the production of prefilled syringes, was found to lead to an increased formation of aggregates of erythropoietin including both dimers covalently linked by disulphide bonds as well as higher-order aggregates. These tungsten-mediated erythropoietin aggregates were finally concluded as the potential root cause for increased immunogenicity observed during the investigational clinical trial with this medicinal product [20] .
An increasing incidence of pure red cell aplasia (PRCA) in patients with chronic kidney disease was observed after subcutaneous use of Eprex® with erythropoietin alpha as active pharmaceutical ingredient in 1998. Leachables derived from the uncoated elastomeric plunger stopper were suspected to be primarily responsible for the formation of anti-erythropoietin antibodies. It was claimed, that the increase in immunogenicity of erythropoietin alpha was due to an adjuvant effect of the leachables from the rubber stopper by polysorbate 80 [21] [22] [23] .
In view of these serious consequences of incompatibilities between container closure materials and susceptible biopharmaceuticals it is crucial to select suitable container closure components and materials when developing a medicinal product with a protein as active substance. The aim of this study was to examine if commercially available, uncoated rubber stoppers compliant with Ph. Eur. 3.2.9 show similar levels of extractables. Furthermore, it was the objective to investigate to what extent substances extracted by organic solvents from the stoppers are also capable to pass into a commonly used biopharmaceutical formulation consisting of an aqueous buffer solution with polysorbate. Finally, it was intended to develop an experimental setup to evaluate the potential impact of the extractables from a rubber stopper on protein stability. Therefore, a highly concentrated aqueous solution with extractables from rubber closures was generated, which was directly miscible with aqueous protein solutions. Because of their already well characterized aggregation behaviour human immunoglobulin G (IgG) [24] and erythropoietin (EPO) were used as model proteins.
Materials and methods

Materials
Human immunoglobulin BRP (cat. no. Y0001512) and erythropoietin BRP (cat. no. E1515000) were purchased from EDQM (Strasbourg, France). Pyrene (puriss., p.a.) and trioctyl trimellitate were obtained from Sigma-Aldrich (Steinheim, Germany). A protein mixture for the calibration of SEC chromatography, containing bovine thyroglobulin (670 kDA), IgA (300 kDa), IgG (150 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and uridine (0.244 kDa) was purchased from Phenomenex (cat. no. AL0-3042, Aschaffenburg, Germany).
Polysorbate 20 and polysorbate 80 were purchased from Caesar & Loretz (Hilden, Germany).
Five bromobutyl closures (BB-1, BB-2, BB-3, BB-4, BB-6) for injection from four different vendors and three chlorobutyl closures (CB-1, CB-2, CB-3) for injection from three different vendors were purchased. All elastomeric closures were non-coated, commercially available and intended for pharmaceutical use and complied with the acceptance criteria of Ph. Eur. 3.2.9 and USP 〈3 8 1〉. In case of absent certificates, the closures were tested for their compatibility with pharmacopoeias (data not shown).
Methods
Extraction studies
Extraction solvents were 2-propanol and water. One elastomeric closure was heated in a 20 mL extraction solvent (3h, reflux). The extraction solvents were heated without rubber stoppers for blank preparation. The extract was evaporated in a vacuum concentrator (Sconcentrator BA-VC-300H, H. Saur Laborbedarf, Germany) with subsequent dilution in 5 mL 2-propanol, sonication, and filtration. The filtrates were subsequently analysed, Pyrene as Internal standard (IS) was added to two samples at final concentrations of 62.5 µg/mL and 1.25 µg/mL to allow for quantitative determination.
Samples were analysed with a gradient RP-HPLC UV method using different HPLC systems (Dionex and Agilent Technologies, column: Prodigy 3u ODS 3 (100A), 150 × 3.00 mm, Phenomenex, Germany; detection wavelengths: 220 and 254 nm (used for quantification); injection volume: 20 µL; column temperature: 40°C). The analysis method was adapted from Andrikopolous et al. [25] : A ternary gradient of ammonium formate buffer pH 3. Starting conditions were 48% A and 52% B held for 5 min, and then B was increased to 100% (ramp 1.6%/min) and held for 5 min. Subsequently, B was decreased to 40% while increasing C to 60% (ramp 7.5%/min). Conditions were held for 7 min. B was increased again to 100% in 1 min with a subsequent adjustment to start conditions within 4 min. The flow rate started at 0.5 mL/min and was held for 35 min, and then the flow rate was increased to 0.6 mL/min in 1 min held for 20 min. Finally, return to start conditions in 4 min.
This RP-HPLC UV method was also used for the forced migration studies, and also for structural identification but with slight modifications.
Forced migration studies
Biopharmaceutical model formulations consisting of 50 mM phosphate buffer pH 6.3 with 0.1 m/m% and 1.0 m/m% PS 80 as well as with 0.1 m/m% and 1.0 m/m% PS 20 were used for the forced migration studies.
Glass vials were filled with 5 mL of each formulation, closed with elastomeric closures, crimped with aluminium covers and stored upside down at 40°C/75% RH for 6 months. Glass tubes filled with same formulations and closed with glass stoppers instead of elastomeric closures were used as blank samples. They were stored in parallel in a normal position. After several storage intervals (1 week, 1, 2, 3, 4 and 6 months) vials and blank sample were sampled, filtered and spiked with 3.7 µg/mL pyrene as IS prior to analysis. The amount of substances (peaks n o 1 to 9) dissolved out from the stoppers by the buffer solution was calculated as trimellitate.
Preparation of concentrated aqueous solution of extractables
10 elastomeric closures (uncut) of type CB-1 and BB-6 each were heated in 100 mL 2-propanol (6 h, reflux). After the evaporation of the solvent, the residue was dissolved in 20 mL of acetonitrile (ACN). Before use, the solution was filtered and diluted with ACN in ratio 1:2 v/v. Two millilitre of this solution were carefully dropped into 50 mL of 0.1 or 1.0 m/v% aqueous PS 20 solution resulting in a concentrated, aqueous based solution of extractables with 0.1% and 1.0% PS 20, respectively. The extractables profiles of the obtained aqueous solutions were verified by RP-HPLC UV method to be qualitatively identical with the extraction profiles obtained by extraction with 2-propanol. Reference solutions contained phosphate buffer, ACN and 0.1 m/v% or 1.0 m/v% PS 20 in the same concentrations, but without rubber extract. This solution is also referred to as 'aqueous solvent system'.
Structural identification with NMR-and MS-spectroscopy
10 elastomeric closures (type CB-1) were heated in 200 mL 2-propanol (6 h, reflux), filtered and evaporated. The oily residue was diluted in 100 mL of 2-propanol and fractionated using a preparative HPLC system (Agilent Technologies, column Prodigy 5u ODS 3 (100A), 250 × 10.00 mm, Phenomenex, Germany). The RP-HPLC UV method was modified for the recording of extraction profiles: For solvent A, ammonium formate buffer pH 3.0 was mixed with ACN/MeOH mixture (ratio 6:4 v/v) in ratio 2:8 v/v. For solvent B, an ACN/MeOH mixture (ratio 6:4 v/v) was mixed with 2-propanol at the ratio of 8:2 v/v. ACN/ MeOH mixture and 2-propanol contained 400 µL/L formic acid.
The start condition was 100% solvent A held for 30 min, then solvent B was increased to 100% (ramp 25%/min). Conditions were held for 31 min, then the system was adjusted back to start conditions in 2 min and held for 3 min. Flow was 5.5 mL/min, injection volume varied, fraction trigger mode was activated from 42 to 58 min with 0.2 mL/test tube. The four fractions obtained were evaporated and the resulting residue was diluted in trichloromethane.
NMR spectra (Avance 500, Bruker Corporation) and MS spectra (Agilent Technologies, Germany; MS detector parameters: APCI source, scan from 100 to 2000 m/z in negative and positive mode, fragmentor voltage: 200 V, capillary voltage: 4000 V, corona current: 4.0 µA positive and 15 µA negative, drying gas: 5.0 L/min at 325°C, nebulizer pressure: 60 psig) were recorded. For MS spectra a slightly modified RP-HPLC method was used: conditions with 40% solvent B and 60% solvent C were held for 12 min, then within 1 min solvent B was increased up to 100% with subsequent adjustment to start conditions within 1 min. Flow rate started at 0.25 mL/min, increased up to 0.30 mL/min with a subsequent decrease to start conditions.
Studies on protein aggregation
Lyophilized human immunoglobulin BRP was reconstituted with Ph. Eur. "Human normal immunoglobulin" [26] buffer to 1.0 mg/mL (IgG stock solution). 25 mL of IgG stock solution were mixed either with a concentrated aqueous solution with extractables in 0.1% PS 20 or with the corresponding reference solution without extractables in a ratio of 1:2 v/v. The preparations were stored in glass centrifuge tubes in parallel, under heat stress conditions (60-64°C, 130 min, drying cabinet Heraeus Kelvitron T, Heraeus Instruments, Germany). Samples were drawn from each glass tube at several storage intervals (0, 30, 50, 70, 90, 110, 130 min).
Soluble IgG aggregates were determined by SEC UV as described by Ph. Eur. Monograph. The molecular weight corresponding with the peak of aggregates was determined by using a protein standard mix (Agilent Technologies, column Biosep-SEC-s2000 column, 300 × 7.80 mm + Security Guard Cartridges GFC-2000, 4 x 3.00 mm, Phenomenex, alternatively a TSKgel G3000PWXL column, 300 × 7.80 mm + TSKgel PWXL Guard Column, 40 × 6.00 mm, Tosoh Bioscience GmbH, Germany, detection wavelengths: 210 and 280 nm, injection volume: 20 µL, stop time: 30 min, flow: 0.5 mL/min). Aggregate peak areas were evaluated as such since differences in the total peak area among test samples with and without extractables precluded an evaluation using area normalisation.
The formation of non-soluble aggregates was controlled by photometric measurement of turbidity at 350 nm (Uvikon-XL, Biotek Instruments GmbH, Germany). This method was adapted from Eckhardt et al. [27] ; reference solutions 1 -4 were prepared according to Ph. Eur. 2.2.1 [28] . Samples and reference solutions were measured in a micro spectrosil ® quartz cuvettes (path length 10 mm, Rotilabo, Carl Roth GmbH + Co. KG, Germany).
Four vials of Erythropoietin BRP were diluted with Ph. Eur. "Erythropoietin concentrated solution" [29] EPO buffer to a final concentration of 0.4 mg/mL (EPO stock solution). The EPO stock solution was mixed with the concentrated aqueous solution of extractables in a ratio of 1:2 v/v (in 0.1 as well as in 1.0% PS 20) or with the corresponding reference solution without extractables. Samples from all preparations were filled into HPLC micro vials, hermetically closed and stored in parallel under heat stress conditions (55°C, 8 days).
Protein aggregation was analysed by SEC UV method as described by the Ph. Eur. monograph (HPLC system and column analogous to IgG analysis, detection wavelength: 214 nm, injection volume: 50 µL, stop time: 60 min). The sum of peak areas eluting before EPO monomer peak in the SEC chromatogram was calculated as total high-molecularweight proteins (HMWPs). Due to the differences in the total peak area among the various test samples, area normalisation was not feasible. Based on blank chromatograms, peaks in the SEC chromatogram deriving from polysorbate were disregarded.
Results
Extraction profiles of commercially available elastomeric closures
The extraction of the rubber stoppers by use of 2-propanol led to the release of various compounds from the stoppers tested. The extraction resulted in rubber stopper specific extraction profiles (Fig. 1, chroma- togram A, C-I). Chlorobutyl rubber stopper CB-1 particularly demonstrated a significantly higher content on extractable compounds (Fig. 1,  chromatogram A) .
Nine peaks became notably obvious (chromatogram A, peaks n°1 -9) accounting for an approximate total amount of 5 mg per stopper calculated as trimellitate. None of these compounds could be extracted from CB-1 when the same extraction conditions were chosen, and water was used as an extraction solvent (Fig. 1, chromatogram B) . Rubber stopper BB-6 (chromatogram I) resulted in an overall quantity of about 0.01 mg of extractables per stopper only.
The CB-1 rubber stopper with its high number of extractables was selected for further studies (chromatogram A). Molar masses and fragmentation pattern indicate that the extractables 6-9 belong to the substance class of trimellitates (Fig. 2) , only differing in varying substituents. Extractables 6 and 9 contain each three identical substituents: either e(CO)eOe(CH 2 ) 7 eCH 3 (extractable 6) or e(CO)eOe(CH 2 ) 9 eCH 3 (extractable 9). Extractable 7 contains two substituents e(CO)eOe(CH 2 ) 7 eCH 3 and one substituent with e (CO)eOe(CH 2 ) 9 eCH 3 , extractable 8 contains two substituents with e (CO)eOe(CH 2 ) 9 eCH 3 and one substituent with e(CO)eOe (CH 2 ) 7 eCH 3 . Because of only slight shift differences in 1 H NMR and 13 C NMR spectra, the allocation of the exact substituent positions was not possible for both extractables and was also beyond the scope of this study.
Identification
Forced migration studies
After 6 months of storage at 40°C/75% RH all extractables 1-9, which had been detected in the 2-propanol extraction profile of CB-1, had leached in detectable amounts into phosphate buffer pH 6.3 containing 1.0 m/m% PS 80 (Fig. 3A) . Even the more lipophilic trimellitates (peaks 6 to 9 in Fig. 3A) . were found to be present in the model formulation consisting of phosphate buffer and 1% PS 80 after 6 months of contact time.
The extent of leaching could be associated with the composition of the biopharmaceutical model formulations. No substances passed into phosphate buffer solutions in the absence of PS 20 or PS 80 ( Fig. 4;  triangles) . However, when PS was added to the phosphate buffer, a considerable leaching was observed after only one week of storage. The Characteristic peaks: t R (peak 1) = 26.0 min, t R (peak 2) = 26.8 min, t R (peak 3) = 27.5 min, t R (peak 4) = 29.1 min, t R (peak 5) = 32.4 min, t R (peak 6) = 43.4 min, t R (peak 7) = 45.7 min, t R (peak 8) = 47.3 min, t R (peak 9) = 48.5 min, Detection wavelength: 220 nm. Fig. 2 . Proposed molecular structure of peak 6, 7, 8, 9 based on MS and NMR data, for substances 7 and 8 the allocation of exact substituent position of e (CH 2 ) 7 eCH 3 and e(CH 2 ) 9 eCH 3 residues was not possible. concentration of the surfactant in the buffer solution turned out to be a decisive factor for the total amount of substances passed into the formulation. A significantly higher amount of these substances was found in the formulation with 1% surfactant compared with 0.1% polysorbate ( Fig. 4 ; rhombus compared with rectangle). Furthermore, the presence of PS 80 at a concentration of 1% led to a higher rate of released compounds than PS 20 when used in the same concentration. Thus, the rate of leaching depends on the type of surfactant and its concentration. In particular, the higher amount of compounds released into phosphate buffer containing 1% PS 80 can be attributed to the higher amount of trimellitates among the leachates (data not shown). Compared with the quantity of extractables found after extraction of CB-1 with 2-propanol, about 0.3 and 0.4% were dissolved out by 0.1% PS 20 and PS 80, respectively. Approximately 2.2 and 4.2% could be detected when 1% PS 20 and PS 80, respectively, was present.
Impact of extractables on IgG and EPO aggregation
The solvent system developed for dissolving CB-1 extractables after the evaporation of 2-propanol was demonstrated to be suitable to study the impact of extractables on protein aggregation. All polar as well as non-polar rubber stopper compounds (peaks 1-9) extracted by 2-propanol remained in solution after dissolving the evaporation residue in the solvent. This was verified by RP-HPLC analysis (see supplemental data). Furthermore, the solvent system containing the extracted compounds was miscible with buffer solutions and compatible with proteins, ensuring sufficient protein stability. The aggregation studies were conducted under worst-case conditions, i.e. by using a highly concentrated extract of CB-1 or BB-6 rubber stoppers in the aqueous solvent system and by applying heat stress conditions for the protein, which allowed evaluating interactions in a short period of time.
The study conditions chosen for IgG (60-64°C for 130 min) were confirmed to be appropriate for a time-dependent increase of IgG aggregates as determined by SEC (Fig. 5 A, grey squares) . The aggregate peak correlated to a molecular weight of approximately 638 kDa. Based on a molecular weight of 150 kDa for the monomeric IgG the formed IgG aggregates are supposed to consist of four IgG monomers. Photometric measurement of the samples did not show any increase in turbidity indicating that the heat stress conditions did not lead to the formation of non-soluble IgG aggregated forms (Fig B grey squares) . However, in the presence of CB-1 extractables in the samples a considerable increase of the formation of non-soluble IgG aggregates could be observed (Fig. 5B black squares) . Correspondingly, the curve of soluble IgG aggregates declined and resulted in an approximately fourfold lower content at the end of the study than in the absence of CB-1 extractables. Moreover, in the presence of CB-1 extractables, total peak area decreased by more than 25% after 130 min. This result further confirms that aggregates different to the soluble IgG aggregates were formed when CB-1 extractables were present. Examples of The impact on IgG aggregation was also studied with a highly concentrated aqueous solution of extractables from rubber closure BB-6 (Fig. 6 ). This rubber stopper distinguished from CB-1 rubber stopper by a very low amount of extractable compounds. There was no significant difference in the formation of IgG aggregates between the test samples containing the concentrated but low amount of BB-6 extractables and the reference samples. This result further underlines the conclusion that CB-1 extractables contributed to the formation of non-soluble IgG aggregates under the heat stress conditions selected.
Samples containing EPO and buffer solution were used to verify adequate stress conditions (55°C for 8 days) in the EPO aggregation studies. An increase of HMWPs and a slight decrease in EPO main peak was observed after eight days of storage at elevated temperatures. Testing EPO in samples containing aqueous solvent system with 0.1% PS 20 solvent without extractables under the chosen heat stress conditions led to a slight increase in HMWPs (Fig. 7, graph A, grey bars) . However, a stronger increase in HMWP amounts was obtained if CB-1 extractables were present in the aqueous solvent system (Fig. 7, graph A, black bars) resulting in an approximately fivefold higher amount of HMWPs after 8 days of heat stress.
This considerable increase of EPO HMWPs in the presence of CB-1 extractables could be prevented if the surfactant concentration was increased to 1.0% PS 20 (Fig. 7, graph B) . In the presence of a tenfold higher content of PS 20 in the test samples, there was no significant difference in aggregate formation between samples with and without CB-1 extractables.
Data evaluation of the SEC chromatograms demonstrated a more pronounced decrease of the main peak in the samples of EPO with the aqueous solvent system than in the samples containing EPO and buffer solution only (exemplary chromatograms are provided in the supplement). This observed EPO instability is supposed to be caused by the aqueous solvent system itself containing ACN and polysorbate. Consequently, samples of EPO with the aqueous solvent system were used as a reference for assessing the impact of CB-1 extractables in the solvent on EPO aggregation.
Discussion
Despite compliance of the tested elastomeric closures with acceptance criteria of Ph. Eur. 3.2.9 and USP 〈3 8 1〉, the extraction profiles showed significant differences when using 2-propanol as the extraction solvent. Extraction of the rubber stopper by heating under reflux with 2-propanol for 3 h resulted in extraction profiles consisting of polar and non-polar substances.
The extractables 6 to 9 of elastomeric closure CB-1 were identified as trimellitates. Trimellitates, especially tris(2-ethylhexyl)trimellitate (TOTM), have been used in recent years as alternative plasticizers for production of polyvinylchloride (PVC) with intended use for medicinal products [30] . This development was mainly triggered by increasing concerns towards negative effects of conventional plasticizers on the health of human beings. Especially phthalates such as di(2-ethylhexyl) phthalate, dibutyl phthalate and benzyl butyl phthalate are considered to be toxic for reproduction [31] [32] [33] and the replacement by alternatives is recommended. Available data for TOTM indicate only a low acute toxic potential [34] . Furthermore, it is reported that TOTM is only poorly absorbed and metabolized [34] and seems therefore a promising alternative to phthalates. Due to their structural characteristics, these substances exhibit poor polarity. Thus, migration into an aqueous based pharmaceutical formulation is decisively depending on the presence of a surfactant and its concentration.
PS is the preferred surfactant in protein-containing pharmaceutical formulations because of its properties to increase protein stability by replacing protein molecules from air-water-interface. The forced migration studies were conducted by applying extreme conditions. PS 20 and 80 were added to the model formulations in higher concentrations than usually used in pharmaceuticals, which typically contain surfactant concentrations between 0.005 and 0.1 m/m%. Furthermore, the storage temperature applied was clearly above the storage temperature usually recommended for biopharmaceuticals. These test conditions were selected in order to force potential migration in short time periods during the studies and had also been proposed by Ding et al to evaluate extractables from elastomeric parts of single-use systems for biomanufacturing applications [9] . However, to better reflect the long contact time between a container closure component and the medicinal product, an exposure time of up to six months was applied in our studies. Under these conditions the extractables 1-9 of CB-1 rubber stopper passed into PS containing phosphate buffer formulations during 6 months of storage, among them the non-polar trimellitates, too.
Thus, the presence of surfactant in an aqueous formulation allowed for leaching of the compounds from the rubber material although extraction with water under reflux for 3 h did not release any of these substances. These results demonstrate that compliance of rubber stoppers with Ph. Eur. Monograph 3.2.9 quality requirements does not ensure a low level of extractables. The results further show that the compounds of the rubber formulation may pass into an aqueous formulation as commonly used for biopharmaceutics if polysorbate is present.
Protein aggregation is a complex process because it is triggered by various mechanisms which can occur in parallel [35] . One main factor is the hydrophobic interaction between partially or fully unfolded proteins to achieve a thermodynamically favourable state [2] . To prevent protein aggregation, the manufacturing and shipping conditions of biopharmaceutical products should be carefully evaluated with respect to temperature and protein concentration. Our study results using model proteins such as IgG and EPO suggest that extractables from primary packaging materials may also affect protein aggregation. The studies with IgG and EPO were conducted under heat stress conditions. These conditions were appropriate to promote protein aggregation and allowed to investigate differences in protein aggregation in the presence and absence of CB-1 extractables. In the case of IgG, CB-1 extract provoked the formation of non-soluble aggregated IgG species which were not formed under the same test conditions without CB-1 extractables. The presence of CB-1 extractables in the test samples with EPO led to a significant increase of soluble HMWPs in comparison to the reference samples of the aqueous solvent system without CB-1 extractables. A conclusion on the extracted compound(s) primarily contributing to protein aggregation is not feasible as the individual extractables were not tested separately.
The results of our study demonstrate that extractables from elastomeric closures have the potential to enhance protein aggregation. Taking this finding into consideration, a further root cause of the PRCA outbreak some years ago might be assumed: the increase of leachables found in Eprex® formulation after the change from human serum albumin to PS might have led to an elevated content of HMWPs of erythropoietin alpha. It is commonly agreed on that protein aggregates in a biotherapeutic product are associated with an enhanced risk for immunogenicity. Seidl et al. had already demonstrated that even a very low quantity of leachables from the primary packaging may be involved in an antibody response due to an enhanced formation of protein aggregates [20] . However, additional investigations would be needed to further support our hypothesis.
The reaction mechanism between elastomeric closure extractables and protein molecules was not studied within the framework of this study. A competition of protein molecules and extractables for PS 20 might be assumed. Both the model proteins as well as the extractables demand for PS, the protein for stabilization and the non-polar extractables to be dissolved in an aqueous solution. In the presence of CB-1 extractables including the non-polar trimellitates in high concentration, the formation of aggregates could not be prevented if the concentration of PS in the formulation was unchanged. The study results with EPO demonstrated that a 10fold increase of PS 20 concentration in the extractables solution could prevent the formation of HMWPs of EPO. Thus, it can be assumed that the formulation buffer with 1.0% PS 20 may provide a sufficient quantity of polysorbate molecules to achieve protein stabilization as well as dissolving non-polar extractables. This assumption was further confirmed by the test results of IgG and BB-6 extractables. In the absence of non-polar extractables as proven by the BB-6 extraction profile, there was no difference in IgG aggregation.
There are different mechanisms discussed on how surfactants like PS 20 contribute to stabilizing proteins. Binding to a partially unfolded protein to reduce aggregation tendency or preventing access to water/ air interfaces are discussed among others [35, 36] . Moreover, a contribution of PS micelles might also be discussed. The final concentrations of the surfactant in the samples were above the critical micelle concentration of 0.007% [37] by use of buffer solution with 1.0% as well as with 0.1% PS 20.
When discussed from the regulatory point of view, results of the forced migration studies and of the studies with IgG and EPO demonstrate two divergent effects when PS is present in the medicinal product formulation. On one hand, PS was identified as an enhancer for leaching substances from rubber stopper material into the formulation. It is assumed that PS enables solubilizing the highly non-polar compounds in an aqueous formulation. This assumption is supported by the results of the forced migration studies which demonstrated the high correlation of the concentration of PS in the formulation and the quantity of leachables measured in the aqueous buffer solution. Regarding this effect, the selected concentration of PS in a biotherapeutic formulation should be as low as possible to minimize leaching. On the other hand, EPO aggregation under stress conditions could be prevented if PS is present in the formulation in a sufficient quantity in order to provide adequate protection. The selection of a suitable rubber stopper with a low level of extractables (and thus, of potential leachables) as well as an optimum PS concentration are key points when developing a biotherapeutic product in order to ensure the efficacy, safety, and quality of the medicinal product. Fig. 7 . Formation of high-molecular weight proteins (HMWPs) of Erythropoietin alpha due to heat stress at 55°C for several days monitored by SEC with UV detection at 214 nm in solutions containing either 0.1% (diagram A) or 1.0% PS 20 (diagram B) with (black bars) or without (grey bars) a mixture of extractables from rubber stopper CB-1, displayed as mean ± SD (n = 4).
Conclusions
This study demonstrates that compliance with the current requirements of Ph. Eur. monograph 3.2.9 does not exclude the presence of potential leachables in later pharmaceutical formulations.
With the current testing procedure for compliance different sum parameters are monitored but the sole use of water as an extraction solvent yields a test solution that does not contain the whole range of potential extractables. Thus, the information gathered from these tests is not satisfactory for quality evaluation of elastomeric stoppers in regard to their level of extractables. In our studies the use of 2-propanol as extraction solvent has proved to be suitable for rubber stopper quality analysis with respect to its extractables profile.
Also, protein-containing drugs as mere aqueous systems must be critically evaluated because of the use of surfactants like polysorbates that can influence the migration behaviour of potential leachables significantly. Surely, in this study extreme conditions have been applied with the intention to accelerate processes that usually occur very slowly. However, the general phenomena involved in potential protein formulation instability remain the same. The experimental design applied in our studies was confirmed to be useful for evaluating the impact of extractables from a selected rubber stopper on protein aggregation in a short period of time.
Consequently, the addition of further test systems to Ph. Eur. 3.2.9 should be discussed for rubber stopper quality evaluation in particular regarding their level of extractables. Moreover, studying the interplay between excipients, leachables, and the particular protein e.g. by incubating closures with relevant protein concentrations but variable surfactant concentrations would allow for a better insight into the interdependent influence of the three factors. This would contribute to the risk assessment on a selected rubber stopper for a protein-containing medicinal product.
